1-2 of 2
Mats Björeman, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

David Marin, Enrica Morra, MD, Mauricette Michallet, Andrzej Hellmann, MD, Dietger Niederwieser, MD, Ernst Schloegl, MD, Mats Björeman, MD, Kajetana Foryciarz, MD, PhD, Aloysius Y Ho, Kazimierz Kuliczkowski, Gert Ossenkoppele, MD, PhD, Antonella Gozzini, MD, M. Lurdes Guerra, MD, Gregor Verhoef, Ave Mori, MD, Miranda Pans, Marc van Baardewijk, Pharm.D, Juan Luis Steegmann, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1689.
https://doi.org/10.1182/blood.V118.21.1689.1689
Published: 2011
Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Bengt Simonsson, MD, Tobias Gedde-Dahl, MD, Berit Markevärn, MD, Kari Remes, MD, Jesper Stentoft, MD, Anders Almqvist, MD, Mats Björeman, MD, Max Flogegård, MD, Heikki Hallman, MD, Perttu Koskenvesa, MD, Anders Lindblom, MD, Claes Malm, MD, Satu Mustjoki, MD, Kristina Myhr-Eriksson, MD, Anu Räsänen, MD, Marjatta Sinisalo, MD, Risto Sippola, MD, Anders Själander, MD, Ulla Strömberg, MD, Ole Weiss Bjerrum, MD, Hans Ehrencrona, MD, Franz Gruber, MD, Veli Kairisto, MD, Karin RN Olsson, Arnon Nagler, MD, Johan Lanng Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo Porkka, MD, for the Nordic CML Study Group (NCMLSG)
Journal: Blood
Blood (2009) 114 (22): 3280.
https://doi.org/10.1182/blood.V114.22.3280.3280
Published: 2009